Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)

Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukemia (CLL) in combination with rituximab (R) or obinutuzumab (G). Our aim was to investigate the addition of bendamustine (B) to these Ven-containing regimens in relapsed/refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara, Kozloff, Mark F., Giever, Thomas, Lozanski, Gerard, Jiang, Yanwen, Huang, Huang, Pignataro, Daniela Soriano, Schary, William, Humphrey, Kathryn, Mobasher, Mehrdad, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561296/
https://www.ncbi.nlm.nih.gov/pubmed/33121235
http://dx.doi.org/10.3324/haematol.2020.261107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561296/
https://www.ncbi.nlm.nih.gov/pubmed/33121235
http://dx.doi.org/10.3324/haematol.2020.261107

Ejemplares similares